EDMONTON, Alberta--(BUSINESS WIRE)--VaxAlta Inc. is pleased to announce a new collaboration with the Faculty of Science at the University of Alberta to advance early stage livestock vaccines research.
“Alberta’s decades-long commitment to glycomics research has brought ground-breaking discoveries”, said Dr. Jonathan Schaeffer, Dean of the Faculty of Science. “Examples of these private-public partnerships, while working collaboratively with our innovation system, means we can move promising discoveries to the marketplace faster while continuing to diversify our economy in areas such as food production and safety.”
The research program builds on the University’s strong history of glycomics research and leadership in harnessing carbohydrates to find new vaccines and drugs that will address pressing challenges in infectious diseases. The $660,000 investment from VaxAlta will support the research and development of glycoconjugate vaccines that target bacterial pathogens that impact animal health and human food safety.
“This investment will result in important research related to the development of critical, safe and effective livestock vaccines. These vaccines will lead to safer foods and will support food producers as they continue to move away from the use of antibiotics on farms,” said Mr. Jason Ding, Acting CFO of VaxAlta Inc., a leading vaccine research and development company based in Edmonton. “We want to acknowledge all of our supporters and partners in the innovation system in Alberta and Canada, and in particular, want to recognize the National Research Council of Canada Industrial Research Assistance Program and TEC Edmonton for their support in this collaboration.”
About VaxAlta Inc.
VaxAlta is a leading glycoconjugate vaccine research and development company based in Edmonton, Alberta. Founded in 2013, the company is focused on developing sugar-based, effective, affordable, and easy to administer livestock vaccines that eliminate the use of antibiotics.
For more information, please visit www.vaxalta.com
